Electronic Health Record (EHR) heart risk calculator

Dr. Ankit Shah, a leading cardiologist with MedStar Health in Baltimore, MD, discusses a promising new tool, an interactive heart risk calculator that will help patients get a quicker and more personal assessment of their risk for heart disease, stroke, and other cardiovascular diseases. MedStar Health patients for the first time will see their heart health information embedded in their electronic health records (EHRs) using an easy-to-read, interactive interface.  It will quickly show patients the impact that their current blood pressure, cholesterol and other risk factors play in their risk of heart disease or stroke.

Read More

Gloucester Marine Genomics Institute Biotechnology Training

The Gloucester Marine Genomics Institute (GMGI) in Gloucester, Massachusetts has recently received Workforce Skills Capital Grants to expand its facilities and purchase biomanufacturing equipment in order to train an even bigger group of Academy students for careers in biotechnology, an industry that is desperate for talent / trained professionals.  Here to talk about this news and the future of training top biotechnology workers to meet the industry’s ever-growing demand is Chief Operating Officer Chris Bolzan.

Read More

Talking openly about brain health

Michelle Dickinson, Author, TED Speaker, and advocate, discusses ways to decrease the mental health stigma and shame that prevents people from accessing care, why we should invest in mental health or brain health in the workplace and her own personal story of perseverance and triumph.

Read More

Vedolizumab (Entyvio®) trial results for crohn’s disease

Dr. Asit Parikh, MD, SVP, and head of the Gastrointestinal Therapeutic Area at Takeda Pharmaceutical Company Limited discusses new data presented at the 15th Congress of the European Crohn’s and Colitis Organisation (ECCO) from the phase 3 VISIBLE 2 clinical trial evaluating the efficacy and safety of an investigational subcutaneous (SC) formulation of vedolizumab (Entyvio®) for use during maintenance therapy in adult patients with moderately to severely active Crohn’s disease (CD).

Read More

Colorectal cancer screening study

Dr. Paul Limburg, a gastroenterology consultant at the Mayo Clinic, and CMO for screening at Exact Sciences, and co-author of this study discusses the results of the colorectal cancer screening study published in the Journal of Medical Screening.  The study indicated high adherence to getting screened with the at-home, stool-based, multi-target DNA test. These findings point to the importance of choice in colorectal cancer (CRC) screening options, as well as the role of patient navigation programs to help with adherence, at a time when 1-in-3 individuals are not up to date on CRC screening.

Read More

SANDD mini™-Sharps and Needle Destruction Device

Darcy Klug, CEO and Chairman of Redhawk Holdings Corp. discusses the SANDD mini–First Responder™ a portable battery-operated sharps and needle destruction device that uses electricity to heat and incinerate needles in seconds leaving no sharp portions.  He also talks about why these devices should be in every hospital, nurse’s office and homeless shelter throughout the country and the success that has been seen in Louisiana.

Read More

New treatment for active Thyroid Eye Disease (TED)

Dr. Raymond Douglas, an oculoplastic surgeon, discusses the approval of TEPEZZA™ (teprotumumab-trbw) for the treatment of Thyroid Eye Disease (TED), the first and only FDA-approved medicine for the treatment of TED. The FDA approval of TEPEZZA™ is supported by a robust body of clinical evidence, including statistically significant, positive results from the Phase 2 clinical study, as well as the Phase 3 confirmatory clinical study OPTIC. Dr. Douglas previously presented at the American College of Rheumatology (ACR) 2019 annual meeting, sharing integrated, pooled phase 2/phase 3 clinical study data that further substantiates that teprotumumab improves the debilitating effects of active TED, including proptosis (eye bulging), diplopia (double vision), quality of life (QoL) and clinical activity score (CAS).  He is joined by Wendy a participant in the TEPEZZA™ trial who saw an improvement in her eye bulging among other symptoms.

Read More